Oncology-related issues of angiotensin-receptor blockers
نویسندگان
چکیده
منابع مشابه
Angiotensin II receptor blockers.
BUMC PROCEEDINGS 2003;16:123–126 The angiotensin II receptor blockers (ARBs) represent a newer class of antihypertensive agents. Their mechanism of action differs from that of the angiotensin-converting enzyme (ACE) inhibitors, which also affect the renin-angiotensin system. The ARBs were developed to overcome several of the deficiencies of ACE inhibitors: competitive inhibition of ACE results ...
متن کاملAngiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues.
Reducing the actions of the renin-angiotensin-aldosterone system with angiotensin-converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs) slows nephropathy progression in patients with or without diabetes. These drug classes have proven therapeutic benefits, particularly in patients with renal insufficiency (ie, serum creatinine level 133-265 micromol/L [1.5-3.0 m...
متن کاملInhibitors of Angiotensin-converting Enzyme or Blockers of Angiotensin-2 Receptor in COVID-19 Patients with Comorbid Cardiovascular or Pulmonary Diseases
Following the skyrocketing spread of SARS-CoV-2 into almost all the countries over five continents, diverse clinical strategies are urgently needed to defeat its pandemic, considering that an magic-bullet antiviral vaccine or treatment is presently unavailable. WHO later proclaimed the viral outbreak as a pandemic. Despite this fast speed of the pandemic, any recommended treatment must first...
متن کاملAngiotensin receptor blockers: baseline therapy in hypertension?
The provocative editorial by Verma and Strauss in the BMJ 5 years ago stating that angiotensin receptor blockers (ARBs) ‘may increase myocardial infarction—and patients may need to be told’ caused a tempest in the teapot and led to extensive scrutiny of outcome data with this drug class. In 2007 the blood pressurelowering treatment trialists collaboration found that there were similar blood pre...
متن کاملAngiotensin II receptor blockers and nephropathy trials.
This is the first of a series of reports on the American Diabetes Association (ADA) 61st Scientific Sessions held in Philadelphia in June 2001. It covers topics related to angiotensin II receptor blockers (ARBs) and nephropathy. At a symposium at the 61st Scientific Sessions of the ADA in June 2001, the results of three recent diabetic nephropathy trials with angiotensin II subtype 1 receptor a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Orvosi Hetilap
سال: 2015
ISSN: 0030-6002,1788-6120
DOI: 10.1556/oh.2015.30118